Corient Capital Partners LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)
Corient Capital Partners LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 51,112 shares of the company’s stock after buying an additional 601 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Corient Capital Partners LLC’s portfolio, making the stock its 14th biggest holding. Corient Capital Partners LLC’s holdings in Johnson & Johnson were worth $6,702,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Davidson Trust Co. raised its holdings in shares of Johnson & Johnson by 6.4% during the 1st quarter. Davidson Trust Co. now owns 20,690 shares of the company’s stock valued at $2,712,000 after buying an additional 1,239 shares during the period. Private Ocean LLC grew its position in shares of Johnson & Johnson by 34.2% in the 1st quarter. Private Ocean LLC now owns 7,643 shares of the company’s stock worth $1,002,000 after acquiring an additional 1,946 shares in the last quarter. Mitchell Capital Management Co. boosted its position in Johnson & Johnson by 1.0% during the 1st quarter. Mitchell Capital Management Co. now owns 9,654 shares of the company’s stock valued at $1,266,000 after purchasing an additional 97 shares during the period. Rhumbline Advisers boosted its position in Johnson & Johnson by 0.3% during the 1st quarter. Rhumbline Advisers now owns 4,272,641 shares of the company’s stock valued at $560,271,000 after purchasing an additional 12,967 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH boosted its position in Johnson & Johnson by 6.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 1,401,320 shares of the company’s stock valued at $183,755,000 after purchasing an additional 90,882 shares during the period. Hedge funds and other institutional investors own 67.66% of the company’s stock.
Shares of NYSE JNJ opened at $146.71 on Friday. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The business’s 50-day moving average price is $146.50 and its two-hundred day moving average price is $142.23. The company has a market capitalization of $389.08 billion, a P/E ratio of 19.41, a price-to-earnings-growth ratio of 3.21 and a beta of 0.71. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.31 and a quick ratio of 1.05.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.75%. The ex-dividend date is Friday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s payout ratio is currently 43.78%.
JNJ has been the topic of several recent analyst reports. Credit Suisse Group reaffirmed a “buy” rating and set a $161.00 target price on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Barclays boosted their price objective on Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Morgan Stanley boosted their price objective on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Wells Fargo & Co raised Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Argus reissued a “buy” rating and issued a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $163.47.
In other news, Director William D. Perez purchased 500 shares of the business’s stock in a transaction on Friday, March 13th. The stock was purchased at an average price of $127.69 per share, with a total value of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares in the company, valued at approximately $2,046,870.70. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.27% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Institutional Investors
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.